1. 185 The Safety and Tolerability of Lumateperone 42 mg for the Treatment of Schizophrenia: A Pooled Analysis of 3 Randomized Placebo-Controlled Trials. (April 2020) Authors: Kane, John M; Vanover, Kimberly E; Durgam, Suresh; Davis, Robert; Satlin, Andrew; Rowe, William; Mates, Sharon; Tamminga, Carol Journal: CNS spectrums Issue: Volume 25:Number 2(2020) Page Start: 316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 186 Results From a 12-Month Open-label Safety Study of Lumateperone (ITI-007) in Patients with Stable Symptoms of Schizophrenia. (April 2020) Authors: Correll, Christoph U.; Vanover, Kimberly E; Durgam, Suresh; Davis, Robert; Rowe, William; Mates, Sharon; Satlin, Andrew Journal: CNS spectrums Issue: Volume 25:Number 2(2020) Page Start: 317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study. (12th March 2019) Authors: Vanover, Kimberly; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Sanchez, Juan; Weingart, Michal; Mates, Sharon; Satlin, Andrew; Davis, Robert Journal: CNS spectrums Issue: Volume 24:Number 1(2019:Feb) Page Start: 190 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Cardiometabolic Safety of Lumateperone (ITI−007): Post Hoc Analyses of Short-Term Randomized Trials and an Open-Label Long-Term Study in Schizophrenia. (April 2021) Authors: Edwards, John B.; Satlin, Andrew; Durgam, Suresh; Davis, Robert E.; Chen, Richard; Mates, Sharon; Correll, Christoph U. Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA. (1st April 2018) Authors: Davis, Robert; Dmitrienko, Alex; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Weingart, Michal; Satlin, Andrew; Mates, Sharon; Correll, Christoph; Vanover, Kimberly Journal: Schizophrenia bulletin Issue: Volume 44(2018)Supplement 1 Page Start: S236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. F46. LUMATEPERONE (ITI-007): FAVORABLE SAFETY PROFILE IN AN OPEN LABEL SAFETY SWITCHING STUDY FROM STANDARD-OF-CARE ANTIPSYCHOTIC THERAPY IN PATIENTS WITH SCHIZOPHRENIA. (1st April 2018) Authors: Davis, Robert; Dmitrienko, Alex; Glass, Steven; Kozauer, Susan; Saillard, Jelena; Weingart, Michal; Satlin, Andrew; Mates, Sharon; Correll, Christoph; Vanover, Kimberly Journal: Schizophrenia bulletin Issue: Volume 44(2018)Supplement 1 Page Start: S236 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Long-Term Lumateperone Treatment in Bipolar Disorder: Six-Month Open-Label Extension Study. (April 2023) Authors: Tohen, Mauricio; Durgam, Suresh; Kozauer, Susan; D'Souza, Ian; Chen, Richard; Mates, Sharon Journal: CNS spectrums Issue: Volume 28:Number 2(2023) Page Start: 233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Lumateperone (ITI−007) in the Treatment of Bipolar Depression: Results from a Randomized Clinical Trial. (April 2021) Authors: D'Souza, Ian; Durgam, Suresh; Satlin, Andrew; Davis, Robert E.; Kozauer, Susan G.; Chen, Richard; Mates, Sharon; Calabrese, Joseph R Journal: CNS spectrums Issue: Volume 26:Number 2(2021) Page Start: 150 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. M205. LONG-TERM SAFETY OF LUMATEPERONE (ITI-007): METABOLIC EFFECTS IN A 1-YEAR STUDY. (18th May 2020) Authors: Satlin, Andrew; Durgam, Suresh; Vanover, Kimberly E; Davis, Robert E; Huo, Jason; Mates, Sharon; Correll, Christoph Journal: Schizophrenia bulletin Issue: Volume 46(2020)Supplement 1 Page Start: S214 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P2‐032: ITI‐007 (LUMATEPERONE) FOR THE TREATMENT OF AGITATION IN PATIENTS WITH DEMENTIA, INCLUDING ALZHEIMER'S DISEASE. (1st July 2006) Authors: Satlin, Andrew; Vanover, Kim; Glass, Steven; Saillard, Jelena; Mates, Sharon; Weingart, Michal; Davis, Robert E. Journal: Alzheimer's & dementia Issue: Volume 14:Supplement 7S(2018)Part 12 Page Start: P678 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗